Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country crawled time : 08:00 save search
AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published: 2024-03-05 (Crawled : 08:00) - biospace.com/
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
lung drug cancer treatment application therapeutics
SELLAS Life Sciences Announces Proposed Public Offering - Jan 04, 2024
Published: 2024-01-04 (Crawled : 08:00) - biospace.com/
SLS | $1.5 -1.32% 530K
|
Health Technology
|
| O: -31.99%
H: 1.66%
C: -5.55%
life offering sciences
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)
Published: 2023-12-12 (Crawled : 08:00) - biospace.com/
LEGN | $47.09 -0.06% 360K
|
Health Technology
|
| O: 0.78%
H: 3.23%
C: 2.76%
carvykti life treatment study
Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023
Published: 2023-12-12 (Crawled : 08:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: -0.57%
H: 0.28%
C: -0.57%
treatment lymphomas potential
Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs
Published: 2023-12-12 (Crawled : 08:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: -0.57%
H: 0.28%
C: -0.57%
unique treatment
Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
Published: 2023-12-11 (Crawled : 08:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.42%
H: 1.23%
C: 1.13%
breyanzi treatment leukemia
Complete Response Letter Received for AVT02 Biologics License Application
Published: 2023-04-14 (Crawled : 08:00) - biospace.com/
ALVO | $13.545 5.08% 150K
|
n/a
|
| O: -14.46%
H: 0.0%
C: -8.97%
TEVA | $12.975 1.53% 3.3M
|
Health Technology
|
| O: -7.13%
H: 1.05%
C: -3.6%
avt02 license application response
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
Published: 2023-03-23 (Crawled : 08:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 5.54%
H: 0.96%
C: 0.96%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 6.53%
H: 0.56%
C: -0.54%
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: 7.34%
H: 0.77%
C: -0.53%
dupixent copd trial potential
Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis
Published: 2023-03-21 (Crawled : 08:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.74%
H: 0.0%
C: 0.0%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 2.13%
H: 0.0%
C: 0.0%
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: 0.71%
H: 0.05%
C: -0.64%
dupixent children six dermatitis approved
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
Published: 2023-03-21 (Crawled : 08:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.74%
H: 0.0%
C: 0.0%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 2.13%
H: 0.0%
C: 0.0%
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: 0.71%
H: 0.05%
C: -0.64%
dupixent children six dermatitis approved
Provention Bio Announces $60 Million Private Placement
Published: 2022-07-08 (Crawled : 08:00) - biospace.com/
PRVB | $24.98 0.08% 9.1M
|
Health Technology
|
| O: 14.43%
H: 0.0%
C: 0.0%
Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation
Published: 2022-04-07 (Crawled : 08:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 4.21%
H: 0.0%
C: -0.61%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 1.74%
H: 0.0%
C: 0.0%
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: -0.3%
H: 2.79%
C: 2.2%
dupixent children
Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares - Mar 16, 2021
Published: 2021-03-16 (Crawled : 08:00) - biospace.com/
BHVN | News 0 d | $40.43 -4.1% 560K
|
Health Technology
|
| O: -4.75%
H: 3.68%
C: -2.33%
offering
TYME Announces $100 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
Published: 2021-02-04 (Crawled : 08:00) - biospace.com/
TYME | $0.3107 -8.21%
|
Health Technology
|
| O: -27.48%
H: 0.39%
C: -11.72%
offering
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.